LEAF-1401

N/A

Report date: 2023/03/12 14:49:27

Base Information

Drug NameLEAF-1401

Drug Alias NameLEAF-1401, a new generation onco-immuno antimetabolite designed to disrupt dysregulated 1-carbon metabolism in cancer and the immune system, is a liposomal formulation of gamma L-pentaglutamated pemetrexed.LEAF-1401

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionThymidylate synthase inhibitors

TargetsThymidylate synthase

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsOvarian Neoplasms +[6]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesL.E.A.F. Pharmaceuticals LLC

China Registration ClassN/A

Develop Information

Active CompaniesL.E.A.F. Pharmaceuticals LLC

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsOvarian Neoplasms +[6]

Inactive IndicationsN/A

Other Information

ATC CodeN/A